Investegate |Sotio Announcements | Sotio: SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting

Sotio
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) --
,
a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting. DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.

Related Keywords

Czech Republic ,Prague ,Praha ,Hlavníesto ,Michael Tattory ,Radek Spisek ,Richard Kapsa ,Lifesci Communications ,Meeting Library ,Media Library ,Positive Biomarker Data ,Ovca Phase ,First Line Ovarian Cancer ,Investegate Announcements ,Investegate Company Announcements ,Sotio ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,செக் குடியரசு ,ப்ராக் ,பிரதா ,ரிச்சர்ட் கப்சா ,சந்தித்தல் நூலகம் ,மீடியா நூலகம் ,ந்வ் ,